Alejandro Herrera-Medina

Salamanca, CL, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 9 publications

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Quantitative MYD88 L265P and flow cytometry levels for outcome determination in IgM gammopathies: the SAL-TO study.

Journal: Blood advances

Published: September 26, 2025

Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).

Development and validation of a novel prognostic index for mantle cell lymphoma integrating TP53 mutations (MIPI53).

Journal: British journal of haematology

Published: July 24, 2025

Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.

Noninvasive genotyping and early disease dynamics demonstrate the efficacy of ibrutinib in combination with immunochemotherapy in patients with mantle cell lymphoma treated in the TRIANGLE trial.

Journal: Leukemia

Published: May 28, 2025

Genetic Evidence against Clonotypic B Lymphocytes as a Reservoir for Plasma-cell Cancers.

Genetic Evidence against Clonotypic B Lymphocytes as a Reservoir for Plasma-cell Cancers.

Journal: Blood cancer discovery

Published: March 28, 2025

Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancers.

Genetic evidence against clonotypic B-lymphocytes as reservoir of plasma-cell cancers.

Journal: Blood cancer discovery

Published: March 28, 2025

Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient.

Single-Cell DNA Sequencing and Immunophenotypic Profiling to Track Clonal Evolution in an Acute Myeloid Leukemia Patient.

Journal: Biomedicines

Published: November 29, 2023

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

The genomic profiling of high-risk smoldering myeloma patients treated with an intensive strategy unveils potential markers of resistance and progression.

Journal: Blood cancer journal

Published: November 09, 2023

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future.

Minimal Residual Disease in Multiple Myeloma: Past, Present, and Future.

Journal: Cancers

Published: June 26, 2023

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.

Ibrutinib in Combination With Rituximab for Indolent Clinical Forms of Mantle Cell Lymphoma (IMCL-2015): A Multicenter, Open-Label, Single-Arm, Phase II Trial.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 14, 2022

Showing 1-9 of 9

Last Updated: 09/26/2026